Biopharma's Technology and Capital Partner

Technology and financing solutions to advance tomorrow’s medicines

A specialist
in healthcare investing

Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 85 partnered commercial and development stage programs. We also maintain and license our Captisol® technology platform with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world.

Diversified Portfolio

Our portfolio includes programs that span disease areas such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and many rare conditions. Today we own economic rights to more than 25 commercial programs, which are marketed in more than 70 countries.

By the Numbers

0 +
portfolio
assets
0 +
marketed products generating royalties
0 +
active Captisol-
partnered programs
$ 0 M+
invested in Q3
and Q4 2023
All figures as of November 30, 2023, unless otherwise indicated.